JP2001517939A - ペプチドによって増強されるトランスフェクション - Google Patents
ペプチドによって増強されるトランスフェクションInfo
- Publication number
- JP2001517939A JP2001517939A JP53989998A JP53989998A JP2001517939A JP 2001517939 A JP2001517939 A JP 2001517939A JP 53989998 A JP53989998 A JP 53989998A JP 53989998 A JP53989998 A JP 53989998A JP 2001517939 A JP2001517939 A JP 2001517939A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- transfection
- composition
- protein
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.1つ以上の核酸分子、1つ以上のペプチドまたはタンパク質、および1つ以 上のトランスフェクション薬剤を含む、細胞をトランスフェクトするための組成 物。 2.前記組成物が、2つ以上のペプチドおよび/またはタンパク質を含む、請求 項1に記載の組成物。 3.前記組成物が、2つ以上のトランスフェクション薬剤を含む、請求項1に記 載の組成物。 4.前記組成物が、ペプチド−核酸複合体またはタンパク質−核酸複合体を含む 、請求項1に記載の組成物。 5.前記ペプチド−核酸複合体またはタンパク質−核酸複合体が、2つ以上のペ プチドもしくはタンパク質または両方を含む、請求項4に記載の組成物。 6.前記トランスフェクション薬剤が、1つ以上のカチオン性脂質を含む、請求 項1に記載の組成物。 7.前記トランスフェクション薬剤が、さらに1つ以上の中性脂質を含む、請求 項6に記載の組成物。 8.前記トランスフェクション薬剤が、1つ以上のデンドリマーを含む、請求項 1に記載の組成物。 9.前記トランスフェクション薬剤が、さらに1つ以上の脂質を含む、請求項8 に記載の組成物。 10.前記カチオン性脂質が、1つ以上の1価カチオン性脂質を含む、請求項6 に記載の組成物。 11.前記1価カチオン性脂質が、DOTMA、DOTAP、DMRIE、およびDDABからなる 群から選択される、請求項10に記載の組成物。 12.前記カチオン性脂質が、1つ以上の多価カチオン性脂質を含む、請求項6 に記載の組成物。 13.前記多価カチオン性脂質が、DOSPA、DOSPER、DOGS、TMTPS、TMTOS、TMTLS 、TMTMS、およびTMDOSからなる群から選択される、請求項12に記載の組成物。 14.前記中性脂質が、DOPE、DPhPE、およびコレステロールからなる群から選 択される、請求項7に記載の組成物。 15.前記デンドリマーが、デンススターデンドリマー、PAMAMデンドリマー、N H3コアデンドリマー、エチレンジアミンコアデンドリマー、ジェネレーション5 以上のデンドリマー、置換基を有するデンドリマー、1つ以上のアミノ酸を含む デンドリマー、グラフト化デンドリマー、および活性化されたデンドリマーから なる群から選択される、請求項8に記載の組成物。 16.1つ以上の前記トランスフェクション薬剤が、1つ以上の前記ペプチドお よび/またはタンパク質に共有結合している、請求項1に記載の組成物。 17.1つ以上の前記カチオン性脂質が、1つ以上の前記ペプチドおよび/また はタンパク質に共有結合している、請求項6に記載の組成物。 18.1つ以上の前記中性脂質が、1つ以上の前記ペプチドおよび/またはタン パク質に共有結合している、請求項7に記載の組成物。 19.1つ以上の前記デンドロマーが、1つ以上の前記ペプチドおよび/または タンパク質に共有結合している、請求項8に記載の組成物。 20.前記ペプチドおよび/またはタンパク質が、動物、細菌、ウイルスのペプ チドおよび/またはタンパク質由来である、請求項1に記載の組成物。 21.前記ペプチドおよび/またはタンパク質が、1つ以上の核酸結合基と結合 している、請求項1に記載の組成物。 22.前記核酸結合基が、少なくとも1つのポリアミンを含む、請求項21に記 載の組成物。 23.前記核酸結合基が、少なくとも1つのスペルミンを含む、請求項22に記 載の組成物。 24.少なくとも1つの前記ペプチドおよび/またはタンパク質が、核局在化タ ンパク質またはペプチドである、請求項1に記載の組成物。 25.少なくとも1つの前記ペプチドおよび/またはタンパク質が、融合誘導ペ プチドまたはタンパク質である、請求項1に記載の組成物。 26.少なくとも1つの前記ペプチドおよび/またはタンパク質が、レセプター −リガンドペプトドまたはタンパク質である、請求項1に記載の組成物。 27.少なくとも1つの前記ペプチドおよび/またはタンパク質が、輸送ペプチ ドまたはタンパク質である、請求項1に記載の組成物。 28.少なくとも1つの前記ペプチドおよび/またはタンパク質が、ウイルス性 ペプチドまたはタンパク質である、請求項20に記載の組成物。 29.前記ウイルスが、インフルエンザウイルス、水疱性口内炎ウイルス、アデ ノウイルス、アルファウイルス、セムリキ森林ウイルス、肝炎ウイルス、ヘルペ スウイルス、HIVウイルス、およびシミアンウイルスからなる群から選択される 、請求項28に記載の組成物。 30.さらにDEAE-デキストラン、クロロキン、またはその組み合わせを含む、 請求項1に記載の組成物。 31.少なくとも1つの前記ペプチドおよび/またはタンパク質が、インスリン 、トランスフェリン、上皮増殖因子、線維芽細胞増殖因子、ラクトフェリン、フ ィブロネクチン、アデノウイルスペントンベース、Knob、およびヘキソンタンパ ク質、水疱性口内炎ウイルス糖タンパク質、セムリキ森林ウイルスコアタンパク 質、インフルエンザ赤血球凝集素、B型肝炎コアタンパク質、HIV Tatタンパク質 、単純ヘルペスウイルスVP22タンパク質、ヒストンタンパク質、HMGタンパク質 、およびインベーシンタンパク質、インターナリンタンパク質、内毒素、ジフテ リア毒素、赤痢菌毒素、メリチン、マガイニン、グラミシジン、セクロフィン、 ディフェンシン類、プロテグリン類、タキプレシン類、チオニン類、インドリシ ジン、バクテネシン、ドロソマイシン、アピダエシン類、カテリシジン、殺菌性 透過性増加タンパク質、ナイシン、ブホリン、およびそのフラグメントからなる 群から選択される、請求項1に記載の組成物。 32.前記組成物が、初代細胞培養物、継代細胞培養物、または細胞株をトラン スフェクトし得る、請求項1に記載の組成物。 33.前記細胞株が、ヒト細胞株である、請求項32に記載の組成物。 34.前記細胞株が、動物細胞株である、請求項32に記載の組成物。 35.前記細胞株が、線維芽細胞である、請求項32に記載の組成物。 36.少なくとも1つの前記ペプチドおよび/またはタンパク質が、同じもしく は異なるペプチドまたはタンパク質の多量体を含む、請求項1に記載の組成物。 37.前記ペプチドおよび/またはタンパク質が、1つ以上のアミノ酸誘導体ま たはアナログを含む、請求項1に記載の組成物。 38.少なくとも1つの前記ペプチドおよび/またはタンパク質が、融合誘導、 核局在化、輸送、レセプター-リガンドおよび細胞接着からなる群から選択され る、2つ以上の機能を含む、請求項1に記載の組成物。 39.標的細胞または組織のトランスフェクションに有効な量の請求項1に記載 の組成物および薬学的キャリアを含む、薬学的組成物。 40.選択された治療用核酸を有する、標的細胞または組織のトランスフェクシ ョンに有効な量の請求項1に記載の組成物を含む、治療用組成物。 41.選択された診断用核酸を有する、標的細胞または組織のトランスフェクシ ョンに有効な量の請求項1に記載の組成物を含む、診断用組成物。 42.ペプチドまたはタンパク質に共有結合したトランスフェクション薬剤の成 分を含む、細胞をトランスフェクトするための組成物。 43.前記トランスフェクション薬剤の成分が脂質である、請求項42に記載の 組成物。 44.前記トランスフェクション薬剤の成分がカチオン性脂質である、請求項4 2に記載の組成物。 45.前記トランスフェクション薬剤の成分が中性脂質である、請求項42に記 載の組成物。 46.前記トランスフェクション薬剤の成分がデンドリマーである、請求項42 に記載の組成物。 47.レセプター-リガンドタンパク質をさらに含む、請求項42に記載の組成 物。 48.1つ以上の核酸分子、1つ以上のペプチドまたはタンパク質、および1つ 以上のトランスフェクション薬剤の組み合わせによって得られる、細胞をトラン スフェクトするための組成物。 49.最初にペプチド-核酸複合体またはタンパク質-核酸複合体を形成し、続い て該ペプチド-核酸複合体またはタンパク質-核酸複合体と凝集し得るトランスフ ェクション薬剤を添加することによって得られる、請求項48に記載の細胞をト ランスフェクトするための組成物。 50.前記ペプチド核酸複合体またはタンパク質核酸複合体が形成された後に、 該複合体がカチオン性脂質および中性脂質の混合物に添加される、請求項49に 記載の組成物。 51.核酸を用いて細胞をトランスフェクトする方法であって、請求項1に記載 のトランスフェクション組成物を該細胞と接触させる工程を包含する、方法。 52.核酸を用いて細胞をトランスフェクトする方法であって、請求項17に記 載のトランスフェクション組成物を該細胞と接触させる工程を包含する、方法。 53.核酸を用いて細胞をトランスフェクトする方法であって、請求項31に記 載のトランスフェクション組成物を該細胞と接触させる工程を包含する、方法。 54.核酸を用いて細胞をトランスフェクトする方法であって、請求項48に記 載のトランスフェクション組成物を該細胞と接触させる工程を包含する、方法。 55.核酸を用いて細胞をトランスフェクトする方法であって、以下の工程: (a)1つ以上のペプチドまたはタンパク質を核酸と混合し、ペプチド-核酸 複合体またはタンパク質-核酸複合体を形成する工程; (b)工程(a)由来の複合体にトランスフェクション薬剤を添加し、該トラ ンスフェクション薬剤および該複合体の凝集体を得る工程;ならびに (c)該細胞を工程(b)由来の凝集体と接触させる工程、 を包含する、方法。 56.前記ペプチドまたはタンパク質が、細胞内局在化シグナル配列、核局在化 シグナル配列、融合誘導配列、輸送またはトラフィッキング配列、レセプター- リガンド配列、または細胞接着配列を含む、請求項55に記載の方法。 57.前記ペプチドまたはタンパク質が、核酸結合基への共有結合によって改変 される、請求項56に記載の方法。 58.前記核酸結合基が、スペルミンである、請求項57に記載の方法。 59.前記ペプチドが、Sp-NLS、Sp-NLSNLS、SP-NLSRGD、Opf-GG-1、Opf-GG-2、 Opf-GG-2-CYS、またはSP-Tatである、請求項58に記載の方法。 60.前記トランスフェクション薬剤がデンドリマーを含む、請求項55に記載 の方法。 61.前記トランスフェクション薬剤が活性化デンドリマーを含む、請求項60 に記載の方法。 62.前記デンドリマーが、GX(NH3)またはGX(EDA)デンドリマーからなる群から 選択され、ここでXは約5から約10の間の整数である、請求項61に記載の方 法。 63.前記デンドリマーがアルギニンまたはリジンに結合している、請求項60 に記載の方法。 64.トランスフェクション薬剤、およびトランスフェクション薬剤のトランス フェクションを増強し得るペプチドもしくはタンパク質、または改変ペプチドも しくはタンパク質を含む、トランスフェクション試薬キット。 65.カチオン性脂質トランスフェクション薬剤を含む、請求項64に記載のキ ット。 66.前記カチオン性脂質トランスフェクション薬剤が、「LIPOFECTAMINE」、 「LIPOFECTIN」、「LIPOFECTACE」、「CELLFECTIN」、「MULTIFECTOR」または「 TRANSFECTIN」からなる群から選択される、請求項65に記載のキット。 67.前記ペプチドがSp-NLSNLSである、請求項66に記載のキット。 68.前記ペプチドがSp-Tatである、請求項66に記載のキット。 69.デンドリマートランスフェクション薬剤を含む、請求項64に記載のキッ ト。 70.前記デンドリマーがデンススターデンドリマーまたは活性化デンドリマー である、請求項69に記載のキット。 71.診断用キットであって、診断用核酸をさらに含む、請求項64に記載のキ ット。 72.核酸結合基への共有結合によって改変されるNLS配列を含む、ペプチド。 73.NLS配列のダイマーまたは多量体を含む、請求項72に記載の改変ペプチ ド。 74.前記核酸結合基がスペルミンである、請求項73に記載の改変ペプチド。 75.核酸結合基への共有結合によって改変された、Tat配列を含む、ペプチド 。 76.Tat配列のダイマーまたは多量体を含む、請求項75に記載の改変ペプチ ド。 77.前記核酸結合基がスペルミンである、請求項76に記載の改変ペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/818,200 US6051429A (en) | 1995-06-07 | 1997-03-14 | Peptide-enhanced cationic lipid transfections |
US08/818,200 | 1997-03-14 | ||
PCT/US1998/005232 WO1998040502A1 (en) | 1997-03-14 | 1998-03-16 | Peptide-enhanced transfections |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001517939A true JP2001517939A (ja) | 2001-10-09 |
JP4265699B2 JP4265699B2 (ja) | 2009-05-20 |
Family
ID=25224940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53989998A Expired - Lifetime JP4265699B2 (ja) | 1997-03-14 | 1998-03-16 | ペプチドによって増強されるトランスフェクション |
Country Status (5)
Country | Link |
---|---|
US (2) | US6051429A (ja) |
EP (2) | EP1007699A4 (ja) |
JP (1) | JP4265699B2 (ja) |
AU (1) | AU6562298A (ja) |
WO (1) | WO1998040502A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006508896A (ja) * | 2002-05-06 | 2006-03-16 | ヌクレオニクス インコーポレーティッド | 核酸の送達法 |
WO2006098463A1 (ja) * | 2005-03-14 | 2006-09-21 | Shinka Soyaku Inc. | ポリ核酸結合物質 |
WO2007001006A1 (ja) | 2005-06-29 | 2007-01-04 | Nrl Pharma, Inc. | 重金属障害改善剤およびそれを含有する医薬組成物、食品、化粧料 |
WO2010024262A1 (ja) * | 2008-08-27 | 2010-03-04 | 株式会社スリー・ディー・マトリックス | トランスフェクション剤 |
JP2012532174A (ja) * | 2009-07-06 | 2012-12-13 | エフ.ホフマン−ラ ロシュ アーゲー | 二重特異性ジゴキシゲニン結合抗体 |
AU2007321235B2 (en) * | 2006-11-17 | 2014-01-16 | Agriculture Victoria Services Pty. Ltd. | Novel sequences of Haemonchus contortus, immunogenic compositions, methods for preparation and use thereof |
JP2017500856A (ja) * | 2013-12-12 | 2017-01-12 | ライフ テクノロジーズ コーポレーション | トランスフェクションの強化のための膜透過性ペプチドならびにそれらを使用する組成物及び方法 |
WO2017213092A1 (ja) * | 2016-06-06 | 2017-12-14 | 和光純薬工業株式会社 | トランスフェクション促進用ペプチド |
JP2018532404A (ja) * | 2015-10-14 | 2018-11-08 | ライフ テクノロジーズ コーポレーション | リボ核タンパク質トランスフェクション薬剤 |
JP2020534812A (ja) * | 2017-09-08 | 2020-12-03 | ライフ テクノロジーズ コーポレイション | 改良された相同組換えおよびその組成物のための方法 |
Families Citing this family (157)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
US6989434B1 (en) * | 1994-02-11 | 2006-01-24 | Invitrogen Corporation | Reagents for intracellular delivery of macromolecules |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US20030069173A1 (en) * | 1998-03-16 | 2003-04-10 | Life Technologies, Inc. | Peptide-enhanced transfections |
US6372720B1 (en) * | 1998-02-05 | 2002-04-16 | Kenneth J. Longmuir | Liposome fusion and delivery vehicle |
SE9803099D0 (sv) * | 1998-09-13 | 1998-09-13 | Karolinska Innovations Ab | Nucleic acid transfer |
US7081495B1 (en) | 1998-09-23 | 2006-07-25 | School Of Pharmacy, University Of London | Cationic compounds and their use as macro molecular carriers |
US7410798B2 (en) | 2001-01-10 | 2008-08-12 | Geron Corporation | Culture system for rapid expansion of human embryonic stem cells |
US6667176B1 (en) | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
EP1129064B1 (en) | 1998-11-12 | 2008-01-09 | Invitrogen Corporation | Transfection reagents |
MXPA01009073A (es) * | 1999-03-10 | 2002-05-06 | Phogen Ltd | Suministro de acidos nucleicos y proteinas a las celulas. |
US6852334B1 (en) * | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
DE19925143A1 (de) * | 1999-06-02 | 2000-12-07 | Aventis Pharma Gmbh | Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie |
GB9914045D0 (en) * | 1999-06-16 | 1999-08-18 | Smithkline Beecham Plc | Novel compounds |
WO2001038547A2 (en) * | 1999-11-24 | 2001-05-31 | Mcs Micro Carrier Systems Gmbh | Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells |
AU782697B2 (en) * | 1999-12-16 | 2005-08-18 | Monsanto Technology Llc | DNA constructs for expression of heterologous polypeptides in plants |
GB9930533D0 (en) * | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
EP1242052A4 (en) * | 1999-12-29 | 2003-07-02 | A James Mixson | HISTIDIN COPOLYMER AND METHODS OF USE THEREOF |
US7070807B2 (en) * | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
US6319715B1 (en) * | 2000-04-21 | 2001-11-20 | Cornell Research Foundation, Inc. | Method of enhancing the delivery of nucleic acids using silica nanoparticles |
WO2001081370A2 (en) * | 2000-04-24 | 2001-11-01 | Novartis Ag | Histone h2a-derived peptides useful in gene delivery |
GB0011938D0 (en) * | 2000-05-17 | 2000-07-05 | Angeletti P Ist Richerche Bio | Improvements relating to gene delivery systems |
EP1285081A2 (en) * | 2000-05-30 | 2003-02-26 | ICH Productions Limited | Improved methods of transfection |
US6902933B2 (en) * | 2000-11-03 | 2005-06-07 | Regents Of The University Of Michigan | Surface transfection and expression procedure |
US7264969B1 (en) * | 2000-11-10 | 2007-09-04 | University Of Utah Research Foundation | Carrier system for specific artery wall gene delivery |
US20030170642A1 (en) * | 2001-03-12 | 2003-09-11 | Irm, Llc | Identification of cellular targets for biologically active molecules |
GB0106315D0 (en) * | 2001-03-14 | 2001-05-02 | Ich Productions Ltd | Transfection complexes |
US20030186390A1 (en) * | 2001-03-22 | 2003-10-02 | De Jong Gary | Methods for delivering nucleic acid molecules into cells and assessment thereof |
US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
WO2002083186A1 (en) * | 2001-04-13 | 2002-10-24 | The Population Council, Inc. | Nuclear receptor-mediated introduction of a pna into cell nuclei |
DE50214200D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
EP1420688A4 (en) * | 2001-06-25 | 2005-08-31 | Us Gov Health & Human Serv | MACROMOLECULAR IMAGING AGENTS FOR LIVER VISUALIZATION |
DE10133307A1 (de) * | 2001-07-12 | 2003-02-06 | Deutsches Krebsforsch | PNA-Konjugat zur Therapie von mit HIV in Zusammenhang stehenden Erkrankungen |
GB0125216D0 (en) * | 2001-10-19 | 2001-12-12 | Univ Strathclyde | Dendrimers for use in targeted delivery |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
FR2834465A1 (fr) * | 2002-01-10 | 2003-07-11 | Synt Em | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisation pour le traitement des maladies du systeme nerveux central |
KR100468316B1 (ko) | 2002-01-29 | 2005-01-27 | 주식회사 웰진 | Dna의 세포 또는 조직 내 전달 효율을 높이는 펩타이드 |
AU2003221584A1 (en) * | 2002-05-01 | 2003-11-17 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
EP1539245A2 (en) * | 2002-06-26 | 2005-06-15 | The Penn State Research Foundation | Methods and materials for treating human papillomavirus infections |
US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
US20040048260A1 (en) * | 2002-09-10 | 2004-03-11 | Fu-Hsiung Chang | Transfection of nucleic acid |
US20040151729A1 (en) * | 2002-10-28 | 2004-08-05 | George Michalopoulos | Novel long-term three-dimensional culture system |
ATE540129T1 (de) * | 2002-11-22 | 2012-01-15 | Univ Johns Hopkins | Target zur therapie kognitiver behinderungen |
US7465708B2 (en) | 2002-11-25 | 2008-12-16 | Mixson A James | Branched cationic copolymers and methods for antimicrobial use |
CA2513072A1 (en) * | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
US20040138154A1 (en) | 2003-01-13 | 2004-07-15 | Lei Yu | Solid surface for biomolecule delivery and high-throughput assay |
US20040219100A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Composition useful for the treatment of tumors |
US20040220121A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Methods for drug delivery |
US20040219104A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Methods for treatment of tumors |
US20040220084A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Methods for nucleic acid delivery |
US20040219101A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Composition useful for treatment of tumors |
US20040220085A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Compositions for nucleic acid delivery |
US20040219103A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Methods useful for the diagnosis, imaging and treatment of tumors |
US20040219102A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Compositions for drug delivery |
US20040219097A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Composition useful for the diagnosis, imaging and treatment of tumors |
US20040220390A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Composition useful for the treatment of tumors |
US20040219099A1 (en) * | 2003-05-02 | 2004-11-04 | Jasbir Sandhu | Method for the treatment of tumors |
US7330851B2 (en) * | 2003-08-18 | 2008-02-12 | Eaglehawk, Limited | Data security through dissembly of data elements or connections between elements |
US20050054100A1 (en) * | 2003-09-08 | 2005-03-10 | Rennard Stephen I. | Methods for fibroblast differentiation |
US7803397B2 (en) * | 2003-09-15 | 2010-09-28 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
US20060040882A1 (en) * | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
WO2006137836A2 (en) * | 2004-08-17 | 2006-12-28 | Research Development Foundation | Bacterial vector systems |
US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
CA2578205A1 (en) * | 2004-08-25 | 2006-03-30 | The Regents Of The University Of Michigan | Partially acetylated dendrimers and related methods of use |
FR2877946B1 (fr) * | 2004-11-12 | 2011-02-11 | Commissariat Energie Atomique | Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
US20060204443A1 (en) * | 2005-03-11 | 2006-09-14 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for tumor treatment using dendrimer conjugates |
CN103361300B (zh) | 2005-03-31 | 2015-04-01 | 斯丹姆涅恩有限公司 | 用高度纯化来自羊膜的细胞群制备的条件培养基 |
EP1733742A1 (en) * | 2005-06-17 | 2006-12-20 | Universiteit Utrecht Holding B.V. | Dendrimers multivalently substituted with active groups |
US20070041934A1 (en) * | 2005-08-12 | 2007-02-22 | Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
EP1984399A4 (en) * | 2006-02-10 | 2010-03-03 | Univ California | TRANSDUCIBLABLE DELIVERY OF SIRANA BY MEANS OF DSRNA BINDEDOMADE FUSIONS TO PTD / CPPS |
US20070281900A1 (en) * | 2006-05-05 | 2007-12-06 | Nastech Pharmaceutical Company Inc. | COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY |
CA2659103C (en) * | 2006-07-12 | 2019-05-21 | The Regents Of The University Of California | Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups |
KR100824396B1 (ko) * | 2006-10-10 | 2008-04-22 | (주)케어젠 | 상피세포 성장인자의 활성을 가지는 펩타이드 및 그의 용도 |
ES2623141T3 (es) | 2007-01-17 | 2017-07-10 | Noveome Biotherapeutics, Inc. | Nuevos métodos para modular respuestas inflamatorias y/o inmunitarias |
WO2009009203A2 (en) * | 2007-04-19 | 2009-01-15 | The Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
US8678686B2 (en) | 2007-05-01 | 2014-03-25 | Pgr-Solutions | Multi-chain lipophilic polyamines |
DK2494993T3 (en) | 2007-05-04 | 2018-11-12 | Marina Biotech Inc | Amino acid lipids and uses thereof |
US7981446B2 (en) * | 2007-11-26 | 2011-07-19 | Forhumantech. Co., Ltd. | Pharmaceutical compositions and methods for delivering nucleic acids into cells |
AU2008342535B2 (en) * | 2007-12-27 | 2015-02-05 | Arbutus Biopharma Corporation | Silencing of polo-like kinase expression using interfering RNA |
CA3044134A1 (en) * | 2008-01-02 | 2009-07-09 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
US8252834B2 (en) | 2008-03-12 | 2012-08-28 | The Regents Of The University Of Michigan | Dendrimer conjugates |
CN102119217B (zh) | 2008-04-15 | 2015-06-03 | 普洛体维生物治疗公司 | 用于核酸递送的新型制剂 |
EP2296669B1 (en) | 2008-05-30 | 2012-03-21 | Yale University | Targeted oligonucleotide compositions for modifying gene expression |
EP3067359A1 (en) | 2008-09-23 | 2016-09-14 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010045512A2 (en) | 2008-10-16 | 2010-04-22 | Mdrna , Inc. | Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
US9017644B2 (en) | 2008-11-07 | 2015-04-28 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
US9023820B2 (en) | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
US8716464B2 (en) * | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
CN102917699A (zh) | 2009-10-13 | 2013-02-06 | 密执安大学评议会 | 树枝状聚合物组合物和合成方法 |
US8912323B2 (en) | 2009-10-30 | 2014-12-16 | The Regents Of The University Of Michigan | Multifunctional small molecules |
US9234179B2 (en) | 2009-12-18 | 2016-01-12 | Shanghai Icell Biotechnology Co., Ltd. | Materials and methods for generating pluripotent stem cells |
WO2011120023A1 (en) | 2010-03-26 | 2011-09-29 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting survivin gene expression uses thereof |
US8455455B1 (en) | 2010-03-31 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes involved in hemorrhagic fever |
WO2011133584A2 (en) | 2010-04-19 | 2011-10-27 | Marina Biotech, Inc. | Nucleic acid compounds for inhibiting hras gene expression and uses thereof |
WO2011139843A2 (en) | 2010-04-28 | 2011-11-10 | Marina Biotech, Inc. | Multi-sirna compositions for reducing gene expression |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
JP5738862B2 (ja) * | 2010-07-10 | 2015-06-24 | 学校法人近畿大学 | 細胞への核酸導入方法および核酸複合体 |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
DK2640700T3 (en) | 2010-11-15 | 2019-01-14 | Life Technologies Corp | AMINOUS TRANSFECTION REAGENTS AND METHODS FOR PREPARING USE THEREOF |
NZ703649A (en) | 2010-12-06 | 2016-08-26 | Penn State Res Found | Compositions and methods relating to proliferative diseases |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
EP2537858A1 (en) * | 2011-06-20 | 2012-12-26 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RS62993B1 (sr) | 2011-10-03 | 2022-03-31 | Modernatx Inc | Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe |
US9402911B2 (en) | 2011-12-08 | 2016-08-02 | The Regents Of The University Of Michigan | Multifunctional small molecules |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP2885313A4 (en) | 2012-08-20 | 2016-03-09 | Univ California | POLYNUCLEOTIDES WITH BIOREVERSIBLE GROUPS |
EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
US9999603B2 (en) | 2013-03-15 | 2018-06-19 | The Penn State Research Foundation | Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3003295A1 (en) | 2013-03-15 | 2016-04-13 | The Penn State Research Foundation | Compositions and methods including celecoxib and plumbagin relating to treatment of cancer |
CN103739674A (zh) * | 2013-04-01 | 2014-04-23 | 中国人民解放军军事医学科学院野战输血研究所 | 系列低分子鱼精蛋白模拟肽及其应用 |
EP2984171A2 (en) | 2013-04-10 | 2016-02-17 | Skau Aps | Peptides having immune suppresive domains for transfection |
US20160120910A1 (en) | 2013-06-25 | 2016-05-05 | Tigenix S.A.U. | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
WO2015042585A1 (en) | 2013-09-23 | 2015-03-26 | Rensselaer Polytechnic Institute | Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
MX2016004249A (es) | 2013-10-03 | 2016-11-08 | Moderna Therapeutics Inc | Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad. |
CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
JP6722598B2 (ja) | 2014-06-30 | 2020-07-15 | ティジェニクス エス.エー.ユー. | 関節リウマチ治療のための間葉系間質細胞 |
SG11201610844PA (en) | 2014-06-30 | 2017-01-27 | Tigenix S A U | Mesenchymal stromal cells for treating sepsis |
WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
RU2572575C1 (ru) * | 2014-10-31 | 2016-01-20 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Средство для внутриклеточной доставки нуклеиновых кислот в клетки млекопитающих |
CN108136050A (zh) | 2015-08-28 | 2018-06-08 | 分子传递有限公司 | 转染络合物和其使用方法 |
RU2611399C1 (ru) * | 2016-01-19 | 2017-02-21 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России | Меченые дендримерные пептиды |
WO2017144552A1 (en) | 2016-02-22 | 2017-08-31 | Centauri Biotech. S.L. | Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso) |
US10538784B2 (en) | 2016-03-01 | 2020-01-21 | Molecular Transfer, Inc. | Plant virus movement proteins and methods of using the same |
GB201604304D0 (en) | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
KR20190058477A (ko) | 2016-08-17 | 2019-05-29 | 솔스티스 바이올로직스, 리미티드 | 폴리뉴클레오티드 구축물 |
AU2017378427A1 (en) | 2016-12-14 | 2019-06-20 | Ligandal, Inc. | Methods and compositions for nucleic acid and protein payload delivery |
WO2018169726A1 (en) * | 2017-03-17 | 2018-09-20 | Centrillion Technologies, Inc. | Hydroxyalkylated polyacrylamide surface coatings for in situ synthesis of dna arrays |
US11013905B2 (en) | 2017-05-11 | 2021-05-25 | Tci Llc | Thermal interconnect for implantable blood pump |
US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
WO2019053295A1 (en) | 2017-09-18 | 2019-03-21 | Fundació Institut D'investigació Sanitària Pere Virgili | METHODS FOR IMPROVING THE EFFICACY OF CELL THERAPY WITH MESENCHYMAL STEM CELL POPULATIONS |
AU2018372631A1 (en) | 2017-11-22 | 2020-05-21 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
AU2019370723A1 (en) | 2018-10-31 | 2021-05-13 | Mesoblast International Sarl | Expansion of hematopoietic stem cells |
KR20210153077A (ko) | 2019-04-16 | 2021-12-16 | 장피트 | 마이크로-rna 의 안정화를 위한 조성물 및 방법 |
US20220175723A1 (en) | 2019-04-22 | 2022-06-09 | The Penn State Research Foundation | Methods and compositions relating to inhibition of aldehyde dehydrogenases for treatment of cancer |
CN111269289B (zh) * | 2020-02-24 | 2023-04-18 | 南京中医药大学 | 从蟾酥中分离得到的肿瘤细胞亲和肽及其筛选方法 |
CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
WO2022235972A1 (en) * | 2021-05-05 | 2022-11-10 | Arcturus Therapeutics, Inc. | Lipid compositions comprising peptide-lipid conjugates |
US20230392188A1 (en) | 2022-06-02 | 2023-12-07 | Perkinelmer Health Sciences, Inc. | Electrophoresis-mediated characterization of dna content of adeno-associated virus capsids |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4507466A (en) | 1983-01-07 | 1985-03-26 | The Dow Chemical Corporation | Dense star polymers having core, core branches, terminal groups |
US4568737A (en) | 1983-01-07 | 1986-02-04 | The Dow Chemical Company | Dense star polymers and dendrimers |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
AU6408586A (en) | 1985-10-03 | 1987-04-24 | Biotechnology Research Partners Limited | Novel lipoprotein-based drug-delivery systems |
US4694064A (en) | 1986-02-28 | 1987-09-15 | The Dow Chemical Company | Rod-shaped dendrimer |
US5560929A (en) * | 1986-08-18 | 1996-10-01 | The Dow Chemical Company | Structured copolymers and their use as absorbents, gels and carriers of metal ions |
US5527524A (en) * | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
US5338532A (en) * | 1986-08-18 | 1994-08-16 | The Dow Chemical Company | Starburst conjugates |
ES2054678T5 (es) | 1986-08-18 | 1997-09-16 | Dow Chemical Co | Conjugados estrella. |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4776288A (en) | 1987-07-31 | 1988-10-11 | Metallgesellschaft Aktiengesellschaft | Method for improving solids distribution in a circulating fluidized bed system |
US5135736A (en) * | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
AU5192190A (en) | 1989-02-24 | 1990-09-26 | City Of Hope | Heterologous block oligomers |
US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
US5198423A (en) | 1989-05-26 | 1993-03-30 | Takara Shuzo Co., Ltd. | Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
ATE156704T1 (de) | 1989-12-05 | 1997-08-15 | Ramsey Foundation | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn |
US5583198A (en) | 1989-12-22 | 1996-12-10 | Commonwealth Scientific And Industrial Research Organization | Amino acids, peptides or derivatives thereof coupled to fats |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5631329A (en) | 1990-08-27 | 1997-05-20 | Dendritech, Inc. | Process for producing hyper-comb-branched polymers |
US5773527A (en) | 1990-08-27 | 1998-06-30 | Dendritech, Inc. | Non-crosslinked, polybranched polymers |
WO1992004221A1 (en) | 1990-09-04 | 1992-03-19 | Jaerlebro Lennart | Training sulky |
US5589392A (en) * | 1991-01-14 | 1996-12-31 | Stratagene | Nucleic acid construct encoding a nuclear transport peptide operatively linked to an inducible promoter |
DE4104186A1 (de) * | 1991-02-12 | 1992-08-13 | Genentech Inc | Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe |
CA2110404A1 (en) | 1991-05-31 | 1992-12-10 | Christina Teng | Human lactoferrin |
AU2160992A (en) | 1991-06-05 | 1993-01-12 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Targeted delivery of genes encoding secretory proteins |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
IL103059A0 (en) * | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
DE4139001A1 (de) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | Verfahren zur einschleusung von nukleinsaeuren in zellen |
US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
ATE260679T1 (de) * | 1992-04-03 | 2004-03-15 | Univ California | Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid |
IL106760A (en) * | 1992-08-25 | 1999-12-31 | Miles Inc | Nuclear Acid Protein Hybrid Structure for Transferring Nucleic Acid from External Source to Cell and Target Nucleus |
US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5266106A (en) * | 1992-10-22 | 1993-11-30 | Xerox Corporation | Ink compositions with dendrimer grafts |
US5574142A (en) * | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5532142A (en) | 1993-02-12 | 1996-07-02 | Board Of Regents, The University Of Texas System | Method of isolation and purification of fusion polypeptides |
EP0693939A1 (de) * | 1993-04-14 | 1996-01-31 | Roche Diagnostics GmbH | Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen |
AU7097494A (en) * | 1993-06-01 | 1994-12-20 | Targeted Genetics Corporation | Envelope fusion vectors for use in gene delivery |
US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
ES2211882T3 (es) * | 1993-07-14 | 2004-07-16 | The Regents Of The University Of California | Sistema de cesion de polinucleotido, automontable que comprende policationes de dendrimeros. |
EP0733103B1 (en) * | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
DE69515645T2 (de) * | 1994-01-28 | 2000-09-21 | Targeted Genetics Corp | Cd69 - transkriptionsregulierende elemente |
US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
DE699079T1 (de) * | 1994-03-07 | 1997-09-25 | Dendritech Inc | Bioaktive und/oder gezielte dendrimere-konjugate |
US5670347A (en) | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
US5777153A (en) * | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
AUPM747694A0 (en) | 1994-08-16 | 1994-09-08 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids and peptides |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5587441A (en) * | 1994-11-08 | 1996-12-24 | Cornell Research Foundation, Inc. | Hyperbranched polymers from AB monomers |
DE69536153D1 (de) | 1994-11-17 | 2011-05-05 | Ich Productions Ltd | Internalisierung von dna, unter verwendung von konjugaten des poly-l-lysins und eines peptidligands des integrin-rezeptors |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
WO1996031549A1 (de) | 1995-04-07 | 1996-10-10 | Mueller Egbert | Dendrimere pfropfpolymerisate |
EP0874910A4 (en) | 1995-06-07 | 1999-04-21 | Life Technologies Inc | ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES |
AUPN741696A0 (en) | 1996-01-05 | 1996-01-25 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids ii |
-
1997
- 1997-03-14 US US08/818,200 patent/US6051429A/en not_active Expired - Lifetime
-
1998
- 1998-03-16 EP EP98911737A patent/EP1007699A4/en not_active Ceased
- 1998-03-16 EP EP09178117A patent/EP2206787A3/en not_active Withdrawn
- 1998-03-16 WO PCT/US1998/005232 patent/WO1998040502A1/en active Application Filing
- 1998-03-16 US US09/039,780 patent/US6376248B1/en not_active Expired - Lifetime
- 1998-03-16 AU AU65622/98A patent/AU6562298A/en not_active Abandoned
- 1998-03-16 JP JP53989998A patent/JP4265699B2/ja not_active Expired - Lifetime
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4868739B2 (ja) * | 2002-05-06 | 2012-02-01 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 核酸の送達法 |
JP2006508896A (ja) * | 2002-05-06 | 2006-03-16 | ヌクレオニクス インコーポレーティッド | 核酸の送達法 |
WO2006098463A1 (ja) * | 2005-03-14 | 2006-09-21 | Shinka Soyaku Inc. | ポリ核酸結合物質 |
WO2007001006A1 (ja) | 2005-06-29 | 2007-01-04 | Nrl Pharma, Inc. | 重金属障害改善剤およびそれを含有する医薬組成物、食品、化粧料 |
AU2007321235B2 (en) * | 2006-11-17 | 2014-01-16 | Agriculture Victoria Services Pty. Ltd. | Novel sequences of Haemonchus contortus, immunogenic compositions, methods for preparation and use thereof |
JP5606318B2 (ja) * | 2008-08-27 | 2014-10-15 | 株式会社スリー・ディー・マトリックス | トランスフェクション剤 |
JPWO2010024262A1 (ja) * | 2008-08-27 | 2012-01-26 | 株式会社スリー・ディー・マトリックス | トランスフェクション剤 |
WO2010024262A1 (ja) * | 2008-08-27 | 2010-03-04 | 株式会社スリー・ディー・マトリックス | トランスフェクション剤 |
US9133484B2 (en) | 2008-08-27 | 2015-09-15 | 3-D Matrix, Ltd. | Transfection agent |
JP2012532174A (ja) * | 2009-07-06 | 2012-12-13 | エフ.ホフマン−ラ ロシュ アーゲー | 二重特異性ジゴキシゲニン結合抗体 |
JP2017500856A (ja) * | 2013-12-12 | 2017-01-12 | ライフ テクノロジーズ コーポレーション | トランスフェクションの強化のための膜透過性ペプチドならびにそれらを使用する組成物及び方法 |
JP2020015747A (ja) * | 2013-12-12 | 2020-01-30 | ライフ テクノロジーズ コーポレーション | トランスフェクションの強化のための膜透過性ペプチドならびにそれらを使用する組成物及び方法 |
JP2018532404A (ja) * | 2015-10-14 | 2018-11-08 | ライフ テクノロジーズ コーポレーション | リボ核タンパク質トランスフェクション薬剤 |
WO2017213092A1 (ja) * | 2016-06-06 | 2017-12-14 | 和光純薬工業株式会社 | トランスフェクション促進用ペプチド |
JPWO2017213092A1 (ja) * | 2016-06-06 | 2019-04-04 | 富士フイルム和光純薬株式会社 | トランスフェクション促進用ペプチド |
JP2020534812A (ja) * | 2017-09-08 | 2020-12-03 | ライフ テクノロジーズ コーポレイション | 改良された相同組換えおよびその組成物のための方法 |
Also Published As
Publication number | Publication date |
---|---|
US6051429A (en) | 2000-04-18 |
US6376248B1 (en) | 2002-04-23 |
EP1007699A4 (en) | 2001-04-11 |
AU6562298A (en) | 1998-09-29 |
JP4265699B2 (ja) | 2009-05-20 |
WO1998040502A1 (en) | 1998-09-17 |
EP1007699A1 (en) | 2000-06-14 |
EP2206787A2 (en) | 2010-07-14 |
EP2206787A3 (en) | 2010-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4265699B2 (ja) | ペプチドによって増強されるトランスフェクション | |
US8058068B2 (en) | Peptide-enhanced transfections | |
JP4338106B2 (ja) | ペプチド増強カチオン脂質トランスフェクション | |
Martin et al. | Peptide-guided gene delivery | |
JP5683533B2 (ja) | 真核細胞のトランスフェクションのための新規試薬 | |
US7915230B2 (en) | Reagents for transfection of eukaryotic cells | |
Liang et al. | Endosomal escape pathways for non-viral nucleic acid delivery systems | |
JP5635512B2 (ja) | 遺伝子調節化合物の改良された送達のための化学的に修飾された細胞透過性ペプチド | |
JP3525393B2 (ja) | 脂質及び例えばリポソーム中でのその使用 | |
US20030220264A1 (en) | Reversible modification of membrane interaction | |
AU2012268867B2 (en) | Novel reagents for transfection of eukaryotic cells | |
Seow et al. | Peptides as promising non-viral vectors for gene therapy | |
Asokan et al. | Strategies for the cytosolic delivery of macromolecules: an overview |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060221 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060519 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060703 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060821 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070801 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080617 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081015 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081204 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20081225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090204 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090210 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
S303 | Written request for registration of pledge or change of pledge |
Free format text: JAPANESE INTERMEDIATE CODE: R316304 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
S803 | Written request for registration of cancellation of provisional registration |
Free format text: JAPANESE INTERMEDIATE CODE: R316803 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120227 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130227 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130227 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140227 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |